Invention Grant
- Patent Title: TRKA kinase inhibitors, compositions and methods thereof
-
Application No.: US15129206Application Date: 2015-03-23
-
Publication No.: US09862716B2Publication Date: 2018-01-09
- Inventor: Helen Mitchell , Mark E. Fraley , Andrew J. Cooke , Craig A. Stump , Yi-Heng Chen , Xu-Fang Zhang , Casey C. McComas , Kathy Schirripa , Melody McWherter , Swati P. Mercer , Keith P. Moore , Ping Liu , Harold B. Wood , Chun Sing Li , Qinghua Mao , Douglas C. Beshore
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Sylvia A. Ayler; John C. Todaro
- Priority: WOPCT/CN2014/074143 20140326
- International Application: PCT/US2015/022004 WO 20150323
- International Announcement: WO2015/148373 WO 20151001
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D513/04
Abstract:
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
Public/Granted literature
- US20170114056A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF Public/Granted day:2017-04-27
Information query
